Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Amyotrophic Lateral Sclerosis - Drugs In Development, 2022, provides an overview of the Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline landscape.

Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathophysiology, with amyotrophy referring to the atrophy of muscle fibers, which are denervated as their corresponding anterior horn cells degenerate. Lateral sclerosis refers to the changes seen in the lateral columns of the spinal cord as upper motor neuron (UMN) axons in these areas degenerate and are replaced by fibrous astrocytes (gliosis). Symptoms include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss.

Report Highlights

Global Markets Direct's Pharmaceutical a...

Summary

GlobalData's clinical trial report, “Multiple Sclerosis - Global Clinical Trials Review, H2, 2021" provides an overview of Multiple Sclerosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Multiple Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain compe...

Summary

Multiple Sclerosis (MS) is a rapidly evolving field in which new developments are constantly influencing the market landscape.

The Dynamic Market Forecast is designed to help clients stay abreast of the latest news in the MS space, including regulatory, commercial, and clinical events as well as understand how all of these events will impact the projected market forecast.

Scope

The Key Events covered in this MS Dynamic Market Forecast include -
- Patent expiration of Gilenya in 2019 and Aubagio in 2023 will affect sales in the 7MM
- Market launch of the second generation S1P receptor modulators, with same MOA as Gilenya will increase competition.
- Two additional anti-CD20 mAbs, similar to marketed Roche’s Ocrevus are expected to launch
- Positive Phase IIb Trial Results of evobrutinib and its novel MOA could offer a new treatment option for MS patients.

Components of the slide deck include -
- Timeline of market-impacting events
- Key clinical trial landscape updates
- Detailed analysis of the most ...

Summary

Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Systemic Sclerosis (Scleroderma) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher -
- Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharma’s view of the disease landscape
- Landscape Updates: ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved product’s lifecycle management initiatives; ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies
- Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
- Approved Product Landscape: An overview of pipeline candidates, containing snapshot...

Summary

GlobalData's clinical trial report, “Tuberous Sclerosis Global Clinical Trials Review, H2, 2018" provides an overview of Tuberous Sclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on Tuberous Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain co...

Summary

Amyotrophic Lateral Sclerosis (ALS) is a motor neuron degenerative disease which affects both upper motor neurons (UMN) and lower motor neurons (LMN). It is a progressive disease, with patients becoming increasingly dependent on carers and physicians as time from onset increases, and ultimately, it is fatal. ALS can be split into two origins, hereditary - which is known as FALS (Familial ALS) or idiopathic - known as SALS (sporadic ALS).

Currently there are only two drugs on the market that are approved for the treatment of ALS; Sanofi’s Rilutek (riluzole) and Mitsubishi Tanabe Pharma’s Radicava (edaravone). The drugs were special cases in terms of FDA approval, they did not meet the normal regulatory requirements for approval but due to the increase in survival of patients they were granted approval.

GlobalData estimates that drug sales for ALS in 2017 were approximately $203M across the seven major markets covered in this report. Over the 10-year forecast period, the market is expected to grow to $1.2B at a CAGR of 19.4%. This growth will ...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Sclerosis - Pipeline Review, H1 2018, provides an overview of the Multiple Sclerosis (Central Nervous System) pipeline landscape.

Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech. The predisposing factors include age, gender, family history and certain infections.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Sclerosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Multiple Sclerosis (Central Nervous System), complete with analysis by stage of develop...

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Progressive Relapsing Multiple Sclerosis (PRMS) Overview 6
Therapeutics Development 7
Pipeline Products for Progressive Relapsing Multiple Sclerosis (PRMS) - Overview 7
Progressive Relapsing Multiple Sclerosis (PRMS) - Therapeutics under Development by Companies 8
Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Progressive Relapsing Multiple Sclerosis (PRMS) - Products under Development by Companies 11
Progressive Relapsing Multiple Sclerosis (PRMS) - Companies Involved in Therapeutics Development 12
Cognosci Inc 12
Genzyme Corp 13
MedImmune LLC 14
VivaCell Biotechnology Espana SL 15
Progressive Relapsing Multiple Sclerosis (PRMS) - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Ass...

Summary

Global Markets Direct’s, ‘Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2016’, provides an overview of the Secondary Progressive Multiple Sclerosis (SPMS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets ...

Summary

GlobalData's clinical trial report, “Multiple Sclerosis Global Clinical Trials Review, H2, 2016" provides an overview of Multiple Sclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on Multiple Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain co...

Summary

GlobalData's clinical trial report, “Relapsing Multiple Sclerosis (RMS) Global Clinical Trials Review, H2, 2016" provides an overview of Relapsing Multiple Sclerosis (RMS) clinical trials scenario. This report provides top line data relating to the clinical trials on Relapsing Multiple Sclerosis (RMS). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to c...

Summary

GlobalData's clinical trial report, “Relapsing Remitting Multiple Sclerosis (RRMS) Global Clinical Trials Review, H2, 2016" provides an overview of Relapsing Remitting Multiple Sclerosis (RRMS) clinical trials scenario. This report provides top line data relating to the clinical trials on Relapsing Remitting Multiple Sclerosis (RRMS). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision m...

Summary

Global Markets Direct’s, ‘Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H1 2016’, provides an overview of the Secondary Progressive Multiple Sclerosis (SPMS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets ...